Postoperative Pain Pipeline Insight

DelveInsight’s, “Postoperative Pain - Pipeline Insight, 2022,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Postoperative Pain Understanding

Postoperative Pain: Overview

Postoperative Pain (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

 

"Postoperative Pain - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Postoperative Pain Emerging Drugs Chapters

This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Postoperative Pain Emerging Drugs

 

VVZ-149: Vivozon

VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating the robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons.

 

Qutenza: Grunenthal

Qutenza (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. It is currently in Phase III stage of development for the treatment of Post-surgical neuropathic pain.

 

CYT-1010: Cytogel Pharma

CYT-1010® is the first member of a new class of drugs, the endomorphins, to reach clinical development.  It produces pain relief through a novel mechanism of action on the endomorphin (EM) receptor. CYT-1010, is entering Phase II clinical development, following a successful Phase I study in humans. This breakthrough pain medicine has shown reduced potential for addiction and significantly less risk of respiratory depression, relative to treatment with traditional pain medicines.

 

ACP-044: ACADIA Pharmaceuticals

ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. A Phase II study was initiated evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in March 2021.

 

CAM2048: Camurus

CAM2048 is a buprenorphine depot formulation for the treatment of postoperative pain providing rapid onset of action and therapeutic buprenorphine plasma levels over a couple of days. CAM2048 is being developed in collaboration with Braeburn Pharmaceuticals and has been successfully evaluated in a completed Phase I trial. The drug is currently being evaluated in Phase I/II stage of development.

 

ST 2427: SiteOne Therapeutics

ST-2427 is an experimental intravenous, non-opioid analgesic for the management of moderate-to-serve severe pain. ST-2427 blocks sodium ion channel 1.7 (NaV1.7).  NaV1.7 is a type of sodium channel that is highly expressed in peripheral nerve fibers that play a critical role in the generation and conduction of pain signals. As ST-2427 does not enter the brain, it is not expected to cause the central nervous system adverse effects (e.g. sedation, nausea, dependence and addition) that plague existing pain therapeutics such as the opioids. The development of ST-2427 was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) under Award Number UG3DA049599.

Further product details are provided in the report……..

Postoperative Pain: Therapeutic Assessment

This segment of the report provides insights about the different Postoperative Pain drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Postoperative Pain

There are approx. 55+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. Phase III include, Vivozon.

Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postoperative Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postoperative Pain therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postoperative Pain drugs.

Postoperative Pain Report Insights

  • Postoperative Pain Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Postoperative Pain Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Postoperative Pain drugs?
  • How many Postoperative Pain drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postoperative Pain?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postoperative Pain therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Postoperative Pain and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

 

 

Introduction

Executive Summary

Postoperative Pain: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Postoperative Pain – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Postoperative Pain companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Postoperative Pain Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

VVZ-149: Vivozon

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

TLC590: Taiwan Liposome Company

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Early Stage Products (Phase I) 

  • Comparative Analysis

ST 2427: SiteOne Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities 

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products 

  • Comparative Analysis

INSB200: InSitu Biologics

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Postoperative Pain Key Companies

Postoperative Pain Key Products

Postoperative Pain- Unmet Needs

Postoperative Pain- Market Drivers and Barriers

Postoperative Pain- Future Perspectives and Conclusion

Postoperative Pain Analyst Views

Postoperative Pain Key Companies

Appendix

List of Table

Table 1: Total Products for Postoperative Pain

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Postoperative Pain

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products      

• Vivozon
• Grunenthal
• Apsen Farmaceutica
• Trevena
• Shijiazhuang Yiling Pharmaceutical
• Haisco Pharmaceutical Group
• Concentric Analgesics
• Salvat
• Unither Pharmaceuticals
• Formosa Pharmaceuticals
• Taiwan Liposome Company
• Novartis
• PainReform
• Oculis Pharma
• Mylan
• McNeil Consumer Pharmaceuticals
• Jiangsu Hengrui Medicine
• Jiangsu Hengrui Medicine
• Adynxx
• Teikoku Pharma USA
• Cali Pharmaceuticals
• ACADIA Pharmaceuticals
• Nevakar
• Cytogel
• Xgene Pharmaceutical
• Arthritis Innovation Corporation
• Mati Therapeutics
• SiteOne Therapeutics
• NeurOp
• Nang Kuang Pharmaceutical
• Flexion Therapeutics
• Hefei Cosource Pharmaceutical
• Layerbio

 

Forward to Friend

Need A Quote